EPC279 | In vivo pharmacokinetics and safety in mice for ultra-long-acting injectable, biodegradable, and removeable in-situ forming implant with cabotegravir for HIV prevention | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC280 | Examining PrEP cascade engagement in a statewide sample of transgender, nonbinary, and gender diverse adults in the United States | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC281 | Designing the next generation intravaginal ring for prevention of HIV and unplanned pregnancy: what do potential users' perceptions have to do with it? | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC282 | Reimagining 'discontinuation' of pre-exposure prophylaxis (PrEP) as part of an ongoing PrEP journey for gay and bisexual men | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC283 | Who prefers what? Correlates of preferences for next-generation HIV prevention products among a national U.S. sample of young MSM | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC284 | What is the added value of incorporating pleasure in sexual health interventions? A systematic review and meta-analysis | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC285 | Disclosure practices among PrEP adopters in the eThekwini district, South Africa | E-poster | Sexuality, gender and prevention technologies (including condoms, treatment as prevention, medical male circumcision, pre-exposure prophylaxis) |
EPC286 | Characterizing history of opioid agonist therapy uptake among people who inject drugs in Iran: findings from a national bio-behavioral surveillance survey in 2020 | E-poster | Access to harm reduction interventions |
EPC287 | Factors associated with preference of 'take-away dose' among Opioid Substitution Therapy clients in Nepal | E-poster | Access to harm reduction interventions |
EPC288 | Partnering with the Ministry of Justice (MOJ) to launch and scale Ukraine's first-ever medication-assisted treatment (MAT) as part of comprehensive HIV prevention services for prisoners with opioid dependency | E-poster | Access to harm reduction interventions |